Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TXN
3. NOW
4. TSLA
5. GOOG
6. CSX
7. IBM
8. KNX
9. LVS
10. INTC

Go back to Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 
(NASDAQ: RVMD) Delayed: 189.69 +6.66 (3.64%)
Previous Close $183.03    52 Week High $ 
Open $182.61    52 Week Low $ 
Day High $193.53    P/E N/A 
Day Low $180.00    EPS $ 
Volume 992,957